

Optimisation of defibrillation for ventricular fibrillation: the use of low tilt waveforms for the defibrillation of ventricular fibrillation

Submission date 01/05/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/07/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 09/07/2013	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Jennifer Adgey

Contact details

Regional Medical Cardiology Centre
Royal Hospitals
Grosvenor Road
Belfast
United Kingdom
BT12 6BA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

RGHT000386

Study information

Scientific Title

Study objectives

Overall survival rates from Ventricular Fibrillation (VF) are currently very poor. A more efficient biphasic defibrillator with novel low-tilt technology could improve the chances of terminating VF early thus increasing the chances of survival. The primary aim of this study is to determine whether the use of a defibrillator with a low-tilt biphasic waveform will improve the success of defibrillation of ventricular fibrillation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

This project has been reviewed and approved by the Office for Research Ethics Committees in Northern Ireland (ORECNI) on the 8th November 2006 (ref: 06/NIR02/108).

Study design

Randomised, controlled, safety and feasibility study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Ventricular fibrillation/cardiac arrest

Interventions

This will be a safety and feasibility study which aims to show equivalence in the removal of ventricular fibrillation during cardiac arrests between a novel low-tilt defibrillating device and the standard-tilted defibrillator currently in use in the trust (Philips Agilent Heartstart XL).

Standard-tilted biphasic defibrillators are currently available on all hospital wards, to the cardiac arrest team and the physician-led cardiac ambulance. Randomisation will occur on a daily basis between the novel low-tilt device and the standard-tilted defibrillator. The randomised device will be made available to the cardiac arrest team, in the coronary care unit and also to the physician-led cardiac ambulance.

It will not be possible to blind those staff delivering the defibrillating shocks to the device in use due to their appearances.

Patients found to be in VF will receive treatment according to the resuscitation guidelines issued by the Resuscitation Council (UK) 2005. The standard-tilted device will deliver shocks at 150 J and the low-tilt device 120 J. Following any three unsuccessful shocks, a rescue shock of 200 J will be used from the standard-tilted defibrillator.

All shocks will be delivered via standard self-adhesive pads which have previously been validated for clinical use. Defibrillating shocks will be delivered by a doctor, nurse or resuscitation officer who is fully trained in advanced life support.

The following non-invasive parameters will also be recorded and analysed:

1. Time from collapse to arrival of emergency services
2. Time to first shock
3. Whether Cardio-Pulmonary Resuscitation (CPR) is performed pre-shock
4. Any delays in shock delivery
5. Duration of arrest
6. Drugs administered
7. Patient demographics
7. Aetiology of VF (where possible)

There will be no follow up of any patients. Patients will only be included in the study at the time of required defibrillation.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

The primary endpoint of the study will be termination of ventricular arrhythmia for greater than or equal to five seconds following shock delivery. This will be determined by analysis of the defibrillator Electrocardiogram (ECG) tracing post-cardiac arrest.

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/12/2006

Completion date

30/11/2007

Eligibility

Key inclusion criteria

All adult patients in cardiac arrest with ventricular fibrillation as the identified rhythm.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

110

Key exclusion criteria

Patients with existing 'Do not resuscitate' orders.

Date of first enrolment

01/12/2006

Date of final enrolment

30/11/2007

Locations

Countries of recruitment

Northern Ireland

United Kingdom

Study participating centre

Regional Medical Cardiology Centre

Belfast

United Kingdom

BT12 6BA

Sponsor information

Organisation

Royal Hospitals Trust (UK)

Sponsor details

Royal Research Office

Grosvenor Road

Belfast

Northern Ireland

United Kingdom

BT12 6BA

Sponsor type

Hospital/treatment centre

Website

<http://www.belfasttrust.hscni.net/>

ROR

<https://ror.org/03rq50d77>

Funder(s)

Funder type

Charity

Funder Name

The Heart Trust Fund (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/11/2007		Yes	No
Results article	results	01/12/2012		Yes	No